<--- Back to Details
| First Page | Document Content | |
|---|---|---|
 Date: 2015-06-19 09:17:51Immunology Immunosuppressants Monoclonal antibodies Autoimmune diseases Biotechnology Infliximab Tumor necrosis factor alpha TNF inhibitor Adalimumab Etanercept Monoclonal antibody therapy Ankylosing spondylitis |
Add to Reading List |
TABLE OF CONTENTS INTRODUCTION 2 | Press release Clinical Phase I Results of GANYMED’s iMAB362 Antibody Demonstrate Excellent Safety Mainz, Germany, August 04, A clinical first-in-human Phase I multi center study with GANYMED’s monoclonal antiDocID: 1r3p4 - View Document |
| TABLE OF CONTENTS INTRODUCTION 2DocID: 1qa0S - View Document |
| 1B-514-C025 Monoclonal Antibody to CD3 Biotin conjugatedmg) Clone:DocID: 1psoS - View Document |
| JUNE 2016 TABLE OF CONTENTS INTRODUCTIONDocID: 1pshE - View Document |
| Microsoft Word - 2006_10_11_eng.docDocID: 1pshm - View Document |